Sky Investment Group LLC Has $9.40 Million Holdings in AbbVie Inc. $ABBV

Sky Investment Group LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 5.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 40,605 shares of the company’s stock after selling 2,219 shares during the quarter. AbbVie makes up 1.6% of Sky Investment Group LLC’s investment portfolio, making the stock its 16th biggest holding. Sky Investment Group LLC’s holdings in AbbVie were worth $9,402,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Breakthru Advisory Services LLC acquired a new position in AbbVie during the 3rd quarter worth about $395,000. Franklin Street Advisors Inc. NC increased its stake in shares of AbbVie by 3.2% in the third quarter. Franklin Street Advisors Inc. NC now owns 178,664 shares of the company’s stock valued at $41,368,000 after buying an additional 5,580 shares during the period. Prentice Wealth Management LLC raised its position in shares of AbbVie by 4.6% during the third quarter. Prentice Wealth Management LLC now owns 6,408 shares of the company’s stock worth $1,484,000 after acquiring an additional 279 shares during the last quarter. Kennebec Savings Bank lifted its stake in shares of AbbVie by 1.6% in the third quarter. Kennebec Savings Bank now owns 9,087 shares of the company’s stock worth $2,104,000 after acquiring an additional 139 shares during the period. Finally, Voya Investment Management LLC boosted its holdings in AbbVie by 22.4% in the third quarter. Voya Investment Management LLC now owns 2,455,380 shares of the company’s stock valued at $568,185,000 after acquiring an additional 449,794 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Guggenheim increased their target price on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research report on Monday, October 20th. Cantor Fitzgerald set a $250.00 price objective on shares of AbbVie and gave the company an “overweight” rating in a research note on Thursday, October 9th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a report on Tuesday, November 4th. Finally, Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $245.84.

AbbVie Stock Up 2.1%

AbbVie stock opened at $227.44 on Friday. The company has a market capitalization of $401.98 billion, a PE ratio of 172.30, a PEG ratio of 1.27 and a beta of 0.36. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The firm’s fifty day moving average is $226.63 and its 200 day moving average is $210.98. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the previous year, the firm posted $3.00 earnings per share. The business’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is currently 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.